PMID- 14737076
OWN - NLM
STAT- MEDLINE
DCOM- 20040324
LR  - 20130304
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 18
IP  - 3
DP  - 2004 Mar
TI  - Abundant expression of fibronectin is a major feature of leukemic dendritic cells 
      differentiated from patients with acute myeloid leukemia.
PG  - 426-33
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells responsible 
      for the initiation of primary immune responses, playing a key role in eliciting 
      effective antitumor immune responses. We reported previously that leukemic blasts 
      from selected patients with acute myeloid leukemia (AML) were able to 
      differentiate in vitro into cells with DC features. In order to identify genes 
      differentially expressed in leukemia-derived DCs (AML-DCs), a polymerase chain 
      reaction (PCR)-based subtraction approach was applied using cDNA from AML-DCs and 
      monocyte-derived DCs from healthy donors as competitors. In the 548 sequences 
      analyzed, 80% corresponded to fibronectin (FN) gene fragments. Overexpression of 
      FN in AML-DCs was demonstrated both by semiquantitative PCR analysis and by 
      immunostaining. In addition, we could show that FN was secreted by AML-DCs. 
      Indeed, FN overexpression was already detectable in AML blasts of M4 and M5 
      subtype, and was significantly induced during DC differentiation after culture. 
      Although the molecular events leading to overexpression of FN and the in vivo 
      relevance of this phenomenon remain to be resolved, leukemic DCs appear to have 
      specific patterns of differentiation, warranting stringent biological and 
      cellular monitoring for the development and testing of leukemic DC-based 
      immunotherapeutic strategies.
FAU - Vialle-Castellano, A
AU  - Vialle-Castellano A
AD  - Laboratoire d'Immunologie des Tumeurs, Institut Paoli-Calmettes, Universite de la 
      Mediterranee, Marseille, France.
FAU - Gaugler, B
AU  - Gaugler B
FAU - Mohty, M
AU  - Mohty M
FAU - Isnardon, D
AU  - Isnardon D
FAU - van Baren, N
AU  - van Baren N
FAU - Olive, D
AU  - Olive D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Fibronectins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Cell Differentiation
MH  - Dendritic Cells/*metabolism/pathology
MH  - Female
MH  - Fibronectins/genetics/*metabolism
MH  - Gene Expression Profiling
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism/pathology
MH  - Leukemia, Myeloid/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism/pathology
MH  - RNA, Messenger/genetics
MH  - RNA, Neoplasm/genetics
MH  - Subtraction Technique
MH  - Up-Regulation
EDAT- 2004/01/23 05:00
MHDA- 2004/03/25 05:00
CRDT- 2004/01/23 05:00
PHST- 2004/01/23 05:00 [pubmed]
PHST- 2004/03/25 05:00 [medline]
PHST- 2004/01/23 05:00 [entrez]
AID - 2403273 [pii]
AID - 10.1038/sj.leu.2403273 [doi]
PST - ppublish
SO  - Leukemia. 2004 Mar;18(3):426-33. doi: 10.1038/sj.leu.2403273.